Seres Therapeutics Inc

NASDAQ:MCRB   3:59:58 PM EDT
22.43
+0.60 (+2.75%)
Products

Seres Therapeutics Announces FDA Clearance Of Ind For Ser-155

Published: 06/01/2021 13:25 GMT
Seres Therapeutics Inc (MCRB) - Seres Therapeutics Announces FDA Clearance of Ind for Ser-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-resistant Bacterial Infections and Graft-versus-host Disease (gvhd).
Seres Therapeutics Inc - Ser-155 Aims to Prevent Mortality in Immunocompromised Patients Due to Gastrointestinal Infections, Bacteremia and Gvhd.
Seres Therapeutics Inc - in Collaboration With Memorial Sloan Kettering Cancer Center, Seres Will Now Advance Ser-155 Into a Phase 1b Clinical Study.